Skip to main navigation
Aprea TherapeuticsAprea Therapeutics

    home

  • Home
  • about

  • About
    • Company
    • Management Team
    • Board of Directors
  • Our Science

  • Our Science
    • p53 in Cancer
    • The Aprea Therapeutics Approach
    • Preclinical Research
    • Clinical Development
  • Pipeline

  • Pipeline
    • Overview
    • APR-246
  • Contact

  • Contact
    • Partnering
    • Contact Us
  • IR Nav

  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Governance
    • Financials
    • Investor Resources

Presentations

Presentations

December 12, 2019
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 1 MB

sub News Events

News & Events

  • Press Releases
  • Events Calendar
  • Presentations

Shareholder Tools

USA

535 Boylston St.
Boston, MA 02116

SWEDEN

Nobels väg 16
SE-171 65 Solna

CONTACT

info@aprea.com

© 2019 Aprea Therapeutics.

    home

  • Home
  • about

  • About
    • Company
    • Management Team
    • Board of Directors
  • Our Science

  • Our Science
    • p53 in Cancer
    • The Aprea Therapeutics Approach
    • Preclinical Research
    • Clinical Development
  • Pipeline

  • Pipeline
    • Overview
    • APR-246
  • Contact

  • Contact
    • Partnering
    • Contact Us
  • IR Nav

  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Governance
    • Financials
    • Investor Resources